Merck (MRK) Tops Q3 EPS by 27c, Revenues Beat; Narrows & Raises FY19 EPS/Revenue Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. HUBS
4. NUE
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Merck (MRK) Tops Q3 EPS by 27c, Revenues Beat; Narrows & Raises FY19 EPS/Revenue Above Consensus

Merck Announces Third-Quarter 2019 Financial Results

October 29, 2019 6:45 AM EDT

Third-Quarter 2019 Worldwide Sales Were $12.4 Billion, an Increase of 15%; Sales Increased 16% Excluding Impact from Foreign Exchange; Growth Driven by Oncology and Human Health Vaccines KEYTRUDA Sales Grew 62% to $3.1 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 64% Human Health Vaccines Sales Grew 17% to $2.5 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 18% Third-Quarter 2019 GAAP EPS was $0.74, an Increase of 1%; Third-Quarter Non-GAAP EPS was $1.51, an Increase of 27% Company Narrows and Raises 2019 Full-Year Revenue Range to be Between $46.5 Billion and $47.0 Billion, Including a Negative Impact from Foreign Exchange of Approximately... More

European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma

October 28, 2019 2:00 PM EDT

ROCKLAND, Massachusetts and NEW YORK, Oct. 28, 2019 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved BAVENCIO® (avelumab) in... More